OTC statins: a bad decision for public health

Lancet. 2004 May 22;363(9422):1659. doi: 10.1016/S0140-6736(04)16284-3.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Coronary Disease / prevention & control
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
  • Hypolipidemic Agents* / adverse effects
  • Nonprescription Drugs*
  • Risk Factors
  • Simvastatin* / adverse effects
  • United Kingdom

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents
  • Nonprescription Drugs
  • Simvastatin